



Certificate of EU product notification

Herewith we confirm that

MT Promedt Consulting GmbH
Altenhofstraße 80
66386 St. Ingbert
Germany

has taken over the function of an European Authorized Representative according to the requirements of Article 10 of the IVDD 98/79/EC for

GenBody Inc.
3-18, Eopseong 2-gil, Seobuk-gu, Cheonan-si
Chungcheongnam-do 31077
Republic of Korea

MT Promedt Consulting GmbH has made the product notification at the relevant competent authority according to Article 10(3).
The in vitro diagnostic medical devices of the manufacturer, covered by the notification, are listed in Annex I of this certificate.

15 June 2020

Dr. Michael Rinck
- Managing Director -

Enclosure
Annex I

**GenBody Inc.**

Annex I
to "Certificate of EU Product Notification"
(List of CE marked Products)

Page 1 / 1 of Annex I

Internal Number	Registration Number (at the German CA/ DIMDI)	Product Category (EDMS)	EDMS Code Description	Classification Annex
GEB-01	DE/CA70/40838- 146964	12 09 01 02 00	Amphetamine/Methamphetamine Specific (+ Ecstasy)	III
GEB-02	DE/CA70/40838- 146965	12 09 01 04 00	Benzodiazepines	III
GEB-03	DE/CA70/40838- 146966	12 09 01 05 00	Cannabinoids	III
GEB-04	DE/CA70/40838- 146967	12 09 01 06 00	Cocaine+ Cocaine Metabolites	III
GEB-05	DE/CA70/40838- 146968	12 09 01 12 00	Morphines	III
GEB-06	DE/CA70/40838- 146771	15 04 80 11 00	Dengue Virus	III
GEB-07	DE/CA70/40838- 152014	15 04 80 04 00	Influenza & Para Influenza	III
GEB-08	DE/CA70/40838- 156158	15 04 80 90 00	Other viral Antigen/ antibody detection	III
GEB-09	DE/CA70/40838- 146969	12 09 01 03 00	Barbiturates	III
GEB-10	DE/CA70/40838- 146970	12 09 01 90 00	Other drug of abuse	III
GEB-11	DE/CA70/40838- 148249	15 04 80 01 00	Adenovirus	III
GEB-12	DE/CA70/40838- 148250	15 04 80 05 00	Respiratory Syncytial Virus (RSV)	III
GEB-13	DE/CA70/40838- 148949	15 01 08 01 00	Mycoplasma Antigen Detection	III
GEB-14	DE/CA70/40838- 152016	26 09	other other clinical instruments	III
GEB-15	DE/CA70/40838- 152027	15 01 04 90 00	Other H. Pylori Reagents	III

15 June 2020

Dr. Michael Rinck
- Managing Director -